Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer.
about
Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinomaSerum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer.Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9.Nuclear translocation of fibroblast growth factor receptor 3 and its significance in pancreatic cancer.Performance status and neutrophil-lymphocyte ratio are important prognostic factors in elderly patients with unresectable pancreatic cancer.Expression and Significances of MTSS1 in Pancreatic Cancer.
P2860
Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 June 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Elevated baseline CA19-9 level ...... dvanced-stage pancreas cancer.
@en
Elevated baseline CA19-9 level ...... dvanced-stage pancreas cancer.
@nl
type
label
Elevated baseline CA19-9 level ...... dvanced-stage pancreas cancer.
@en
Elevated baseline CA19-9 level ...... dvanced-stage pancreas cancer.
@nl
prefLabel
Elevated baseline CA19-9 level ...... dvanced-stage pancreas cancer.
@en
Elevated baseline CA19-9 level ...... dvanced-stage pancreas cancer.
@nl
P2093
P2860
P1433
P1476
Elevated baseline CA19-9 level ...... dvanced-stage pancreas cancer.
@en
P2093
Elizabeth Trolli
Ludmila Katherine Martin
Tanios Bekaii-Saab
P2860
P2888
P304
P356
10.1007/S12032-012-0278-9
P577
2012-06-24T00:00:00Z